Indivior PLC

Executive Summary

Indivior PLC is a specialty pharmaceutical company focused on addiction treatment, primarily opioid use disorder, with marketed products SUBOXONE and SUBLOCADE. Despite a challenging R&D environment—evidenced by two terminated Phase 3 trials for SUBLOCADE—the company maintains a strong commercial franchise and is advancing pipeline candidates for substance use disorders and serious mental illness. Recent strategic shifts aim to diversify beyond opioids, targeting broader CNS indications. Financially, Indivior benefits from recurring revenue from its established products, though it faces patent expiration and generic competition. The company's ability to execute on its pipeline and defend market share will be critical for long-term growth.

Upcoming Catalysts (preview)

• Q4 2026SUBLOCADE label expansion or new indication data40% success
• Q2 2026Pipeline candidate IND filing or Phase 2 data readout for new mental health indication50% success
• Q3 2026Generic SUBOXONE litigation outcome or settlement70% success